Chemical subgroup
L04AF – Janus-assoziierte Kinase (JAK)-Inhibitoren
22Decisions
62Patient groups
Added benefit by patient group
- Considerable3
- Minor4
- Not proven55
Decisions, newest first
- 2025-11-06RinvoqUpadacitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-05-02OlumiantBaricitinibNot proven
- 2024-05-02OlumiantBaricitinibNot proven: 2 of 2 patient groups
- 2024-05-02OlumiantBaricitinibNot proven: 3 of 3 patient groups
- 2024-05-02OlumiantBaricitinibNot proven: 2 of 2 patient groups
- 2023-10-19RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2023-10-05SotyktuDeucravacitinibNot proven: 2 of 2 patient groups
- 2023-02-16RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2023-02-16RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2022-06-16XeljanzTofacitinibNot proven: 2 of 2 patient groups
- 2022-05-19JyselecaFilgotinibNot proven: 2 of 2 patient groups
- 2022-03-03XeljanzTofacitinibNot proven: 5 of 5 patient groups
- 2022-02-17XeljanzTofacitinibNot proven: 6 of 6 patient groups
- 2022-02-17RinvoqUpadacitinibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-07-15RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2021-07-15RinvoqUpadacitinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-05-06OlumiantBaricitinibNot proven
- 2021-04-15JyselecaFilgotinibMinor: 1 of 6 patient groupsNot proven: 5 of 6 patient groups
- 2020-07-16RinvoqUpadacitinibConsiderable: 1 of 7 patient groupsMinor: 1 of 7 patient groupsNot proven: 5 of 7 patient groups
- 2019-02-21XeljanzTofacitinibNot proven: 2 of 2 patient groups
- 2019-02-21XeljanzTofacitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-09-21OlumiantBaricitinibNot proven: 4 of 4 patient groups
Data status: 2026-10-29